System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Rohit Bhatia is an expert in Neurology at Chitkara University (India). As of November 2026, ScienceLeadR ranks Rohit Bhatia in the top 1% of experts worldwide for Cerebrovascular Disorders, Drug Discovery and Drug Development. Rohit Bhatia has authored 683 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 1 of them ongoing. SLR score: 1,860 (community average: 125). How the SLR is computed.

LeadR Profile

Rohit Bhatia Chitkara University India
1 860 ScienceLeadR Reputation 1860

Unlock

Register Login
Network Map

Neurology

Subspecialties: Pharmacy - Biochemistry - Cardiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1987 - 2026
Source: PubMed

All India Institute of Medical Sciences

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 683

Citations

Citations: 10 081 1st author: 95 Last author: 119 Unique author: 8

Main journals

Ann Indian Acad Neurol 57
Neurology 39
Stroke 30
J Commun Dis 23
Neurol India 23

Best Journals

Lancet Glob Health 1
Lancet Neurol 1
N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Heterocyclic scaffolds targeting IDO1: progress in medicinal chemistry and clinical development.
PMID 42815525 — chemistry, pharmaceutical, neoplasms, imidazoles, azoles, therapeutics		Future Med Chem20260
Recent advances in scaffold-based KRAS G12C inhibitors: SAR and biological evaluation insights.
PMID 42936580 — cells, neoplasms, carcinoma, non-small-cell lung, therapeutics, mutation, pyrimidines		RSC Med Chem20260
Tribal ethnicity also identifies particularly vulnerable persons with epilepsy: A cross-sectional study from Central India.
PMID 42906341 — epilepsy, cross-sectional studies, therapeutics		Epilepsy Behav20260
Neolignans as emerging anticancer leads: Isolation, chemical diversity, structure-activity relationships.
PMID 42784935 — cells, drug development, pharmaceutical preparations, structure-activity relationship, chemistry, pharmaceutical, pharmacology		Eur J Med Chem20260
Thiazole-based Anticancer Agents: Synthetic Strategies, Molecular Mechanisms, Comparative Structure-activity Relationships, and Rational Design Perspectives.
PMID 42864804 — cells, thiazoles, structure-activity relationship, antineoplastic agents, chemistry, pharmaceutical, neoplasms, therapeutics, apoptosis		Mini Rev Med Chem20260

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 3
Phase 2 1
Phase 4 1

By status:

Completed 2
Unknown 2
Recruiting 1

By type:

Interventional 5

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 1
multicentricup10 3

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Indian Trial of Tranexamic Acid in Spontaneous Intracerebral Haemorrhage
NCT05836831 — injections, stroke, tranexamic acid, hemorrhagic stroke, antihypertensive agents, therapeutics		Phase 4Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS